Halozyme Q3 revenue $209M (+80% YoY); GAAP EPS $0.44, non-GAAP $0.74

HALOZYME THERAPEUTICS, INC.

2022-Q3 EPS reported $1.02 revenue$478,620,000

Royalty revenue $99.6M (+70% YoY) driven by DARZALEX SC and Phesgo.
Reiterates FY 2022 revenue guidance $655-685M; non-GAAP EPS $2.10-2.25.
Completed $720M convertible notes offering; repurchased $200M shares YTD.
Antares Pharma acquisition contributed product sales; operating income $83.3M.
Partner milestones: Roche Tecentriq SC met endpoints, argenx BLA for efgartigimod SC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue $209 million, EPS $0.44. Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $209 million
EPS: $0.44
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue for the third quarter was $209 million compared to $115.8 million for the third quarter of 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-22-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.